Methamphetamine (METH) abuse is common among individuals infected with HIV-1 and has been shown to affect HIV replication and pathogenesis. These HIV-1 infected individuals also exhibit greater neuronal injury and higher cognitive decline. HIV-1 proteins, specifically gp120 and HIV-1 Tat, have been earlier shown to affect neurocognition. HIV-1 Tat, a viral protein released early during HIV-1 replication, contributes to HIV-associated neurotoxicity through various mechanisms including production of pro-inflammatory cytokines, reactive oxygen species and dysregulation of neuroplasticity. However, the combined effect of METH and HIV-1 Tat on neurocognition and its potential effect on neuroplasticity mechanisms remains largely unknown. Therefore, the present study was undertaken to investigate the combined effect of METH and HIV-1 Tat on behavior and on the expression of neuroplasticity markers by utilizing Doxycycline (DOX)-inducible HIV-1 Tat (1-86) transgenic mice. Expression of Tat in various brain regions of these mice was confirmed by RT-PCR. The mice were administered with an escalating dose of METH (0.1 mg/kg to 6 mg/kg, i.p) over a 7-day period, followed by 6 mg/ kg, i.p METH twice a day for four weeks. After three weeks of METH administration, Y maze and Morris water maze assays were performed to determine the effect of Tat and METH on working and spatial memory, respectively. Compared with controls, working memory was significantly decreased in Tat mice that were administered METH. Moreover, significant deficits in spatial memory were also observed in Tat-Tg mice that were administered METH. A significant reduction in the protein expressions of synapsin 1, synaptophysin, Arg3.1, PSD-95, and BDNF in different brain regions were also observed. Expression levels of Calmodulin kinase II (CaMKII), a marker of synaptodendritic integrity, were also significantly decreased in HIV-1 Tat mice that were treated with METH. Together, this data suggests that METH enhances HIV-1 Tat-induced memory deficits by reducing the expression of pre-and postsynaptic proteins and neuroplasticity markers, thus providing novel insights into the molecular mechanisms behind neurocognitive impairments in HIV-infected amphetamine users.
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Introduction
Despite the availability of combination antiretroviral therapy (cART), HIV-1 infected patients remain at risk of developing HIV-associated neurocognitive disorders (HAND). The prevalence of the most severe form of HAND, HIV-associated dementia (HAD), has declined in the post-cART era (Valcour, 2011; Maschke, 2000) . However, patients continue to suffer from minor forms of HAND, namely asymptomatic neurocognitive impairment (ANI) and minor neurocognitive disorder (MND) (Nightingale, 2014; Heaton, 2010) . Moreover; evidence also indicates a shifting pattern of neurocognitive impairment in HIV patients, from deficits in motor ability, the speed of information processing, and verbal speed in the pre-cART era to deficits in memory and executive function in the post-cART era (Heaton, 2011) . HIV-1 infection in the brain is characterized by the presence of activated astrocytes (Ton and Xiong, 2013) , decreased number of neurons (Kaul et al., 2001) , alterations in dendritic and synaptic densities (Atluri, 2013; Everall, 1999) , decreased expression of synaptic plasticity genes (Atluri, 2013) , and decreased dopaminergic transporters (Chang, 2008) . The development HAND and pathological changes observed in HIV-1 infected individuals can be attributed to direct and indirect toxic effects of HIV viral proteins (gp120, Nef, Tat, and Vpr) released from infected 
